204 related articles for article (PubMed ID: 33727829)
1. Complete Response to Pembrolizumab in Advanced Colon Cancer Harboring Somatic POLE F367S Mutation with Microsatellite Stability Status: A Case Study.
Chen J; Lou H
Onco Targets Ther; 2021; 14():1791-1796. PubMed ID: 33727829
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K; Masetti M; Pfarr N; Lorenzen S
Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
[TBL] [Abstract][Full Text] [Related]
3. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
Dong S; Zakaria H; Hsiehchen D
Oncologist; 2022 Mar; 27(3):159-162. PubMed ID: 35274726
[TBL] [Abstract][Full Text] [Related]
4. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
5. POLE somatic mutations in advanced colorectal cancer.
Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
[TBL] [Abstract][Full Text] [Related]
6. POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.
Bikhchandani M; Amersi F; Hendifar A; Gangi A; Osipov A; Zaghiyan K; Atkins K; Cho M; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hitchins M; Gong J
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239414
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
8. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
9. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
[TBL] [Abstract][Full Text] [Related]
10. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with
Li S; Zhang J; Du W; Ren X; Zhang X
Gland Surg; 2022 Sep; 11(9):1562-1567. PubMed ID: 36221285
[TBL] [Abstract][Full Text] [Related]
12. Immune profiling of microsatellite instability-high and polymerase ε (
Wang C; Gong J; Tu TY; Lee PP; Fakih M
J Gastrointest Oncol; 2018 Jun; 9(3):404-415. PubMed ID: 29998005
[TBL] [Abstract][Full Text] [Related]
13. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Sakamoto H; Tanaka H; Shiratori T; Baba K; Ishioka Y; Itoga M; Taima K; Hasegawa Y; Takanashi S; Tasaka S
Mol Clin Oncol; 2019 Jun; 10(6):610-614. PubMed ID: 31031976
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
16. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
18. Assessment of
Zhu M; Cui H; Zhang L; Zhao K; Jia X; Jin H
Transl Cancer Res; 2022 Jan; 11(1):193-205. PubMed ID: 35261896
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study.
Guo T; Ding Y; Chen L; Zhu L; Lin J; Zhang J; Huang Y; Li W; Lin R; Pan X
J Thorac Dis; 2021 Jan; 13(1):282-290. PubMed ID: 33569208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
